Brief international cognitive assessment for MS (BICAMS) and NEDA maintenance in MS patients: A 2‐year follow‐up longitudinal study DOI Creative Commons
Elisa Leveraro, Maria Cellerino, Caterina Lapucci

et al.

European Journal of Neurology, Journal Year: 2024, Volume and Issue: 32(1)

Published: Dec. 21, 2024

Abstract Background The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) has been validated in many cross‐sectional studies. However, longitudinal data on BICAMS subset trajectories and their correlation with disease activity during follow‐up are scarce. Objectives We aimed to (i) assess changes MS patients initiating high‐efficacy disease‐modifying‐treatments (DMTs), (ii) compare these based maintenance of “no‐evidence‐of‐disease‐activity” (NEDA‐3) status over 24 months, (iii) determine baseline clinical parameters predictive cognitive changes. Methods enrolled 101 (mean age:40,45 ± 11; Relapsing–Remitting‐MS:81%) highly‐effective‐DMTs. Patients underwent Expanded Disability Status Scale (EDSS), BICAMS, Hospital Anxiety Depression (HADS), at after months. Regression‐based change index (RB‐CI) had used evaluation follow‐up. Results During follow‐up, 78 (77.3%) maintained NEDA‐3 status. Considering a 90% confidence levels RB‐CI, 12 (11.9%) improved SDMT, 13 (12.9%) CVLT‐II BVMT‐R; while 7 (6.9%) were classified as worsened 11 (10.9%) 8 (7.9%) BVMT‐R. SDMT scores significantly the entire group ( p = 0.003) maintaining < 0.001). multivariable regression model assessing improvement n 12; z 1.65), was significant explained 21% variance 0.038; Nagelkerke R 2 0.212). Lower EDSS proved be an independent predictor reliable 0.027) our sample. Conclusions Our findings showed that early control—especially low disability—may yield benefits even terms performance.

Language: Английский

Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges DOI
Jeremy Chataway, Thomas Williams, Vivien Li

et al.

The Lancet Neurology, Journal Year: 2024, Volume and Issue: 23(3), P. 277 - 301

Published: Feb. 15, 2024

Language: Английский

Citations

29
A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis DOI Creative Commons
Michael Barnett, Dongang Wang, Heidi Beadnall

et al.

npj Digital Medicine, Journal Year: 2023, Volume and Issue: 6(1)

Published: Oct. 19, 2023

Modern management of MS targets No Evidence Disease Activity (NEDA): no clinical relapses, magnetic resonance imaging (MRI) disease activity and disability worsening. While MRI is the principal tool available to neurologists for monitoring clinically silent and, where appropriate, escalating treatment, standard radiology reports are qualitative may be insensitive development new or enlarging lesions. Existing quantitative neuroimaging tools lack adequate validation. In 397 multi-center scan pairs acquired in routine practice, we demonstrate superior case-level sensitivity a integrated AI-based over (93.3% vs 58.3%), relative consensus ground truth, with minimal loss specificity. We also equivalence AI-tool core trial lab lesion brain volumetric measures, including percentage volume (PBVC), an accepted biomarker neurodegeneration (mean PBVC -0.32% -0.36%, respectively), whereas even severe atrophy (>0.8% loss) was not appreciated reports. Finally, additionally embeds meaningful, experiential comparator that returns relevant patient centile burden, revealing, our cohort, inconsistencies descriptors used image quantitation enhances accuracy of, value-adds to, reporting. Scaled deployment these will open path precision patients MS.

Language: Английский

Citations

27
Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients DOI Creative Commons
Anas Elgenidy,

Nagham Nader Abdelhalim,

Mohammed Al-mahdi Al-kurdi

et al.

Frontiers in Neurology, Journal Year: 2024, Volume and Issue: 15

Published: April 18, 2024

Recent years have seen the emergence of disease-modifying therapies in multiple sclerosis (MS), such as anti-cluster differentiation 20 (anti-CD20) monoclonal antibodies, aiming to modulate immune response and effectively manage MS. However, relationship between anti-CD20 treatments immunoglobulin G (IgG) levels, particularly development hypogammaglobulinemia subsequent infection risks, remains a subject scientific interest variability. We aimed investigate intricate connection MS treatments, changes IgG associated risk infections.

Language: Английский

Citations

10
Cognitive progression independent of relapse in multiple sclerosis DOI
Tom Fuchs, Menno M. Schoonheim, Robert Zivadinov

et al.

Multiple Sclerosis Journal, Journal Year: 2024, Volume and Issue: 30(11-12), P. 1468 - 1478

Published: Aug. 28, 2024

Substantial physical-disability worsening in relapsing-remitting multiple sclerosis (RRMS) occurs outside of clinically recorded relapse. This phenomenon, termed progression independent relapse activity (PIRA), is yet to be established for cognitive decline.

Language: Английский

Citations

9
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis DOI Creative Commons
Pietro Iaffaldano,

Giuseppe Lucisano,

Tommaso Guerra

et al.

Annals of Clinical and Translational Neurology, Journal Year: 2024, Volume and Issue: 11(8), P. 2008 - 2015

Published: July 5, 2024

No direct comparisons of the effect natalizumab and ocrelizumab on progression independent relapse activity (PIRA) relapse-associated worsening (RAW) events are currently available. We aimed to compare risk achieving first 6 months confirmed PIRA RAW irreversible Expanded Disability Status Scale (EDSS) 4.0 6.0 in a cohort naïve patients treated with or from Italian Multiple Sclerosis Register.

Language: Английский

Citations

7
Epstein–Barr Virus and Human Endogenous Retrovirus in Japanese Patients with Autoimmune Demyelinating Disorders DOI Open Access
Davide Cossu, Yuji Tomizawa, Leonardo A. Sechi

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(24), P. 17151 - 17151

Published: Dec. 5, 2023

Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocytes glycoprotein-antibody disease (MOGAD) are distinct autoimmune demyelinating disorders characterized by varying clinical pathological characteristics. While the precise origins of these diseases remain elusive, a combination genetic environmental factors, including viral elements, have been suggested as potential contributors to their development. Our goal was assess occurrence antibodies against pathogenic peptides associated with Epstein-Barr virus (EBV) human endogenous retrovirus-W (HERV-W) in serum samples obtained from Japanese individuals diagnosed MS, NMOSD, MOGAD make comparisons group healthy controls (HCs). We conducted retrospective analysis involving 114 participants, comprising MS (34), NMOSD (20), HCs (40). These were tested using peptide-based enzyme-linked immunosorbent assay. A marked increase antibody response EBV nuclear antigen 1 (EBNA1)386-405 observed patients, compared HCs. Notably, we correlation between EBNA1386-405 HERV-W486-504 subset antibody-positive patients. findings emphasize involvement pathogenesis potentially MOGAD, suggesting its role reactivation HERV-W.

Language: Английский

Citations

14
Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world context DOI
Luca Prosperini, Serena Ruggieri, Shalom Haggiag

et al.

Multiple Sclerosis Journal, Journal Year: 2024, Volume and Issue: 30(10), P. 1309 - 1321

Published: July 31, 2024

To summarize the current evidence on relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) through a quantitative synthesis real-world studies.

Language: Английский

Citations

6
The contribution of tumor necrosis factor to multiple sclerosis: a possible role in progression independent of relapse? DOI Creative Commons
Valentina Mazziotti, Francesco Crescenzo, Ermanna Turano

et al.

Journal of Neuroinflammation, Journal Year: 2024, Volume and Issue: 21(1)

Published: Aug. 21, 2024

Tumor necrosis factor (TNF) is a pleiotropic cytokine regulating many physiological and pathological immune-mediated processes. Specifically, it has been recognized as an essential pro-inflammatory implicated in multiple sclerosis (MS) pathogenesis progression. MS chronic disease of the central nervous system, characterized by multifocal acute inflammatory demyelination white grey matter, along with neuroaxonal loss. A recent concept field research disability resulting from Progression Independent Relapse Activity (PIRA). PIRA recognizes that accumulation since early phase can occur independently relapse activity overcoming traditional dualistic view either relapsing-inflammatory or progressive-neurodegenerative disease. Several studies have demonstrated upregulation TNF expression both active brain lesions. Additionally, elevated levels observed serum cerebrospinal fluid patients. appears to play significant role maintaining intrathecal inflammation, promoting axonal damage neurodegeneration, consequently contributing progression accumulation. In summary, this review highlights current understanding its receptors progression, specifically focusing on relatively unexplored condition. Further area holds promise for potential therapeutic interventions targeting mitigate

Language: Английский

Citations

5
Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis DOI
Shitiz Sriwastava, Mahmoud Elkhooly, S. M. Amatya

et al.

Journal of Neuroimmunology, Journal Year: 2024, Volume and Issue: 390, P. 578315 - 578315

Published: Feb. 17, 2024

Language: Английский

Citations

3
The time to include cognition in the multiple sclerosis concept of progression independent from relapse activity is now DOI
Stefano Ziccardi, Maddalena Guandalini, Tom Fuchs

et al.

Multiple Sclerosis Journal, Journal Year: 2024, Volume and Issue: 30(11-12), P. 1402 - 1404

Published: Aug. 28, 2024

Progression independent of relapse activity (PIRA) has been recently proposed in multiple sclerosis (MS) as a model identifying continuous silent progression disability without the manifestation new clinical and magnetic resonance imaging (MRI) events that contribute to MS worsening. Despite evidence suggesting manifestations often affect cognitive functioning importance neuropsychological monitoring over time, attention is lacking, PIRA concept does not include measure function. In this personal viewpoint, we highlight need cognition have more comprehensive understanding patients with MS.

Language: Английский

Citations

3